DST and tuberculosis: The finding that BPa +JSF-3285 has sterilizing efficacy comparable to that of BPaL in this study suggests that combining a KasA inhibitor such as JSF-3285 with BPa could provide an effective alternative regimen or regimen backbone to BPaL for RR/MDR-TB and, if sufficient safety is demonstrated, DS-TB.